UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report(Date of earliest event reported): December 17, 1999
U.S. Microbics, Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Colorado 0-14213 84-0990371
-------- ------- ----------
(State or other juris- (Commission File Number) (IRS Employer
diction of incorporation) Identification No.)
5922-B Farnsworth Court
Carlsbad, CA 92008
---------------------------------------------------
(address of principal executive offices and zip code)
Registrant's telephone number, including area code:(760)918-1860
Former name or former address, if changed since last report: N/A
<PAGE>
Item 4. Changes in Registrant's Certifying Accountant
Registrant has re-engaged Bradshaw Smith & Co. LLP as its independent certifying
accountant effective December 6th, 1999 dismissing Arthur Andersen LLP its prior
independent certifying accountant, as of the same date. The change in
independent certifying accountant was approved by the Board of Directors of the
Registrant on November 22nd, 1999.
Arthur Andersen LLP was engaged as the Company's auditors on March 12th,
1999. Arthur Andersen LLP has performed tax services for the Registrant during
the interim period of time. There were no disagreements between Registrant and
Arthur Andersen LLP on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Arthur Andersen LLP, would
have precluded them from performing an audit of Registrant. The Registrant's
dismissal of Arthur Andersen LLP was part of the Registrant's cost reduction
program.
(a) Exhibit 16.1
Letter from Arthur Andersen LLP to the Securities and Exchange Commission
dated December 17, 1999.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
U.S. Microbics, Inc.
Date: December 17, 1999 By: /s/ Robert C. Brehm
--------------------------------------
Robert C. Brehm, President and Chief
Executive Officer
By: /s/ Conrad Nagel
--------------------------------------
Conrad Nagel, Chief Financial Officer
EXHIBIT 16.1
December 17, 1999
Office of the Chief Accountant
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington D. C. 20549
Dear Sir/Madam,
We have read Item 4 included in the Form 8-K/A dated December 17, 1999 of U.S.
Microbics, Inc. to be filed with the Securities and Exchange Commission and are
in agreement with the statements contained therein.
Very truly yours,
/s/ Arthur Andersen LLP
ARTHUR ANDERSEN LLP
